芦卡帕利治疗与DNA损伤修复基因改变相关的转移性去势抵抗性前列腺癌:2期TRITON2研究的最终结果
TRITON2是一项2期研究,纳入277例转移性去势抵抗性前列腺癌(mCRPC)患者,按基因改变分组。最终结果显示,BRCA亚组客观缓解率(ORR)为46%(37/81),PALB2亚组为100%(4/4),其他DDR基因组为25%(3/12);ATM、CDK12、CHEK2亚组无客观缓解。结论认为芦卡帕利在BRCA或部分非BRCA DDR基因改变患者中具有临床获益且安全性可控。
要点
- BRCA亚组经独立影像学评估的ORR为46%(37/81),PALB2亚组为100%(4/4)。
- ATM、CDK12、CHEK2亚组均无患者达到客观缓解。
- BRCA亚组PSA50应答率为53%(95%CI 46-61%),PALB2亚组为55%(95%CI 23-83%)。
核心结论
- 最终TRITON2结果证实芦卡帕利在mCRPC患者(包括BRCA或部分非BRCA DDR基因改变者)中具有临床获益且安全性可控。
研究设计与样本
- TRITON2(NCT02952534)为2期研究,纳入既往接受过一或两线下一代雄激素受体靶向治疗和一种紫杉烷类化疗后进展的mCRPC患者,截至2021年7月27日(研究关闭)共入组277例。
主要发现
- 经独立影像学评估的ORR在BRCA亚组为46%(37/81,95%CI 35-57%),PALB2亚组为100%(4/4,95%CI 40-100%),其他DDR基因组为25%(3/12,95%CI 5.5-57%)。
- ATM、CDK12、CHEK2亚组均无患者经独立影像学评估达到客观缓解。
- PSA50应答率在BRCA亚组为53%(95%CI 46-61%),PALB2亚组为55%(95%CI 23-83%),ATM亚组为3.4%(95%CI 0.4-12%),CDK12亚组为6.7%(95%CI 0.2-32%),CHEK2亚组为14%(95%CI 0.4-58%),其他DDR基因组为23%(95%CI 5.0-54%)。
关键数值与推荐
- 主要终点为客观缓解率(ORR),采用修改版实体瘤疗效评价标准1.1版/前列腺癌临床试验工作组3标准,由独立影像学评估。
- 关键次要终点为前列腺特异性抗原(PSA)应答率(较基线下降≥50%[PSA50])。
- 患者按突变基因分组:BRCA(n=172)、ATM(n=59)、CDK12(n=15)、CHEK2(n=7)、PALB2(n=11)、其他DDR基因(n=13)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Initial TRITON2 (NCT02952534) results demonstrated the efficacy of rucaparib 600 mg BID in patients with metastatic castration-resistant prostate cancer (mCRPC) associated with a BRCA1 or BRCA2 (BRCA) or other DNA damage repair (DDR) gene alteration. OBJECTIVE: To present the final data from TRITON2. DESIGN, SETTING, AND PARTICIPANTS: TRITON2 enrolled patients with mCRPC who had progressed on one or two lines of next-generation androgen receptor-directed therapy and one taxane-based chemotherapy. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was objective response rate (ORR; as per the modified Response Evaluation Criteria in Solid Tumor Version 1.1/Prostate Cancer Clinical Trials Working Group 3 criteria in patients with measurable disease by independent radiology review [IRR]); prostate-specific antigen (PSA) response rate (≥50% decrease from baseline [PSA50]) was a key secondary endpoint. RESULTS AND LIMITATIONS: As of July 27, 2021 (study closure), TRITON2 had enrolled 277 patients, grouped by mutated gene: BRCA (n = 172), ATM (n = 59), CDK12 (n = 15), CHEK2 (n = 7), PALB2 (n = 11), or other DDR gene (Other; n = 13). ORR by IRR was 46% (37/81) in the BRCA subgroup (95% confidence interval [CI], 35-57%), 100% (4/4) in the PALB2 subgroup (95% CI, 40-100%), and 25% (3/12) in the Other subgroup (95% CI, 5.5-57%). No patients within the ATM, CDK12, or CHEK2 subgroups had an objective response by IRR. PSA50 response rates (95% CI) in the BRCA, PALB2, ATM, CDK12, CHEK2, and Other subgroups were 53% (46-61%), 55% (23-83%), 3.4% (0.4-12), 6.7% (0.2-32%), 14% (0.4-58%), and 23% (5.0-54%), respectively. CONCLUSIONS: The final TRITON2 results confirm the clinical benefit and manageable safety profile of rucaparib in patients with mCRPC, including those with an alteration in BRCA or select non-BRCA DDR gene. PATIENT SUMMARY: Almost half of TRITON2 patients with BRCA-mutated metastatic castration-resistant prostate cancer had a complete or partial tumor size reduction with rucaparib; clinical benefits were also observed with other DNA damage repair gene alterations.
引用
- Abida W, Campbell D, Patnaik A, et al. Rucaparib for the Treatment of Metastatic Castration-resistant Prostate Cancer Associated with a DNA Damage Repair Gene Alteration: Final Results from the Phase 2 TRITON2 Study. Eur Urol. 2023. PMID: 37277275. doi:10.1016/j.eururo.2023.05.021
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。